Bronchoalveolar lavage fluid cfDNA liquid biopsy-guided neoadjuvant lazertinib in resectable EGFR-mutant non-small cell lung cancer: a prospective phase II study.
We evaluated the feasibility of bronchoalveolar lavage fluid cell-free DNA liquid biopsy (BALiquid) as a preoperative epidermal growth factor receptor (EGFR) genotyping platform and assessed the clinical efficacy of neoadjuvant lazertinib in patients with potentially resectable EGFR-mutant NSCLC. BALiquid-guided neoadjuvant lazertinib demonstrated meaningful antitumor activity, favorable surgical outcomes, and an acceptable safety profile in patients with potentially resectable EGFR-mutant NSCLC. © AME Publishing Company.
We evaluated the feasibility of bronchoalveolar lavage fluid cell-free DNA liquid biopsy (BALiquid) as a preoperative epidermal growth factor receptor (EGFR) genotyping platform and assessed the clinical efficacy of neoadjuvant lazertinib in patients with potentially resectable EGFR-mutant NSCLC. BALiquid-guided neoadjuvant lazertinib demonstrated meaningful antitumor activity, favorable surgical outcomes, and an acceptable safety profile in patients with potentially resectable EGFR-mutant NSCLC. © AME Publishing Company.
What the study was
- Study design
- Clinical trial (phase)
- Population
- n=128
- Sample size
- n=128
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Translational lung cancer research
Why it surfaced
⚪ PROMISING_PRELIMINARY — Promising but preliminary; Watchlist: Early cancer detection (liquid biopsy, ctDNA, cfDNA); Design: Clinical trial (phase); species: unknown
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.